Drug Law Weekly

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Law Weekly


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Financials

Immtech Reports Fiscal Year End 2007 Results

For the fiscal year ended March 31, 2007, revenues increased to $4,318,000, as compared to $3,575,000 for the fiscal year ended March 31, 2006. The increase was primarily attributable to revenues from research and testing agreements. Loss from operations for the year ended March 31, 2007 was reduced to $11,662,000, as compared to a loss from operations of $15,736,000 for the year ended March 31, 2006. The loss was largely due to expenses related to the Phase III clinical trials offset by the Neurochem litigation award of approximately $1,875,000. Net loss attributable to...

• View Other Issues of Drug Law Weekly
  
• View Other NewsRx Publications